Interferon-alpha reinstates morphine-conditioned place preference through opioid receptors in rats

Behavioural Pharmacology

Volumn 20, Issue 2, 2009, Pages 166-173

  Lang, Jun Yuan ^a   Wang, Ji Shi ^a   Zhai, Hai Feng ^b   Fang, Qin ^a   Wu, Ping ^b   Lu, Lin ^b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Conditioned place preference; Neuromodulator; Opioid receptors; Rat; Recombinant human interferon alpha; Relapse

Indexed keywords

ALPHA INTERFERON; MORPHINE; NALOXONE; NEUROTRANSMITTER; OPIATE RECEPTOR; RECOMBINANT ALPHA INTERFERON; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; MALE; NEUROMODULATION; NONHUMAN; PLACE PREFERENCE; RAT; REINFORCEMENT; RELAPSE; ANIMAL; DRUG POTENTIATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ANIMALS; CONDITIONING (PSYCHOLOGY); EXTINCTION, PSYCHOLOGICAL; INJECTIONS, INTRAVENTRICULAR; INTERFERON-ALPHA; MALE; MORPHINE; NALOXONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID;

EID: 66549091448     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832a805e     Document Type: Article

References (61)

1. Asada-Kubota MT, Ueda T, Nakashlma M, Kobayashi M, Shlmada K, Takeda K, et al. (1997). Localization of 2′,5′-oligoadenylate synthetase and the enhancement of its activity with recombinant interferon-alpha A/D in the mouse brain. Anat Embryol (Berl)195:251-257.
2. Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 153:31-43.
3. Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN (2007). Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther29:131-138.
4. Bethus I, Stlnus L, Goodall G (2003). Chronic interferon-alpha potentiates latent Inhibition In rats. Behav Brain Res144:167-174.
5. Blalock JE, Smith EM (1980). Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci USA77:5972-5974.
6. Blalock JE, Smith EM (1981). Human leukocyte interferon (HulFN-alpha): potent endorphin-like opioid activity. Biochem Biophys Res Commun101:472-478.
7. Dafny N (1983a). Interferon modifies EEG and EEG-IIke activity recorded from sensory, motor, and limbic system structures in freely behaving rats. Neurotoxicology4:235-240.
8. Dafny N (1983b). Interferon modifies morphine withdrawal phenomena in rodents. Neuropharmacology22:647-651.
9. Dafny N (1983c). Modification of morphine withdrawal by interferon. Life Sci32:303-305.
10. Dafny N (1984). Interferon: a candidate as the endogenous substance preventing tolerance and dependence to brain opioids. Prog Neuropsychopharmacol Biol Psychiatry8:351 -357.
11. Dafny N, Reyes-Vazquez C (1987). Single injection of three different preparations of alpha-interferon modifies morphine abstinence signs for a prolonged period. Int J Neurosci32:953-961.
12. Dafny N, Yang PB (2005). Interferon and the central nervous system. Eur J Pharmacol523:1-15.
13. Dafny N, Zielinksi M, Reyes-Vazquez C (1983). Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides3:453-463.
14. Dafny N, Lee JR, Dougherty PM (1988). Immune response products alter CNS activity: interferon modulates central opioid functions. J Neurosci Res19:130-139.
15. De La Garza R II, Asnis GM (2003). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res977:70-79.
16. De Wit H, Stewart J (1983). Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology (Berl)79:29-31.
17. Dieperink E, Willenbring M, Ho SB (2000). Neuropsychiatrie symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry157:867-876.
18. Dougherty PM, Pearl J, Krajewski KJ, Pellis NR, Dafny N (1987). Differential modification of morphine and methadone dependence by interferon alpha. Neuropharmacology26:1595-1600.
19. Drescher KM, Whittum-Hudson JA (1997). Evidence for induction of interferonalpha and interferon-beta in retinal glial cells of Muller. Virology234: 309-316.
20. Dunn AL, Crnic LS (1993). Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun7:104-111.
21. Fahey B, Hickey B, Kelleher D, O'Dwyer AM, O'Mara SM (2007). The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogeniv-like effects in healthy rats. Behav Brain Res182:80-87.
22. Garcia-Sastre A, Biron CA (2006). Type 1 interferons and the virus-host relationship: a lesson in détente. Science312:879-882.
23. Ho BT, Lu JG, Huo YY, Fan SH, Meyers CA, Tansey LW, et al. (1994). The opioid mechanism of interferon-alpha action. Anticancer Drugs5:90-94.
24. Jewell NA, Vaghefi N, Mertz SE, Akter P, Peebles RS Jr, Bakaletz LO, et al. (2007). Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol81:9790- 9800.
25. Jiang CL, Son LX, Lu CL, You ZD, Wang YX, Sun LY, et al. (2000). Analgesic effect of Interferon-alpha via mu opioid receptor In the rat. Neurochem Int36:193-196.
26. Katafuchl T, Kondo T, Yasaka T, Kubo K, Take S, Yoshimura M (2003). Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience120:837-845.
27. Katafuchl T, Kondo T, Take S, Yoshimura M (2005). Enhanced expression of brain Interferon-alpha and serotonin transporter in immunologically induced fatigue In rats. Eur J Neurosci22:2817-2826.
28. Kentner AC, James JS, Miguelez M, Bielajew C (2007). Investigating the hedonic effects of interferon-alpha on female rats using brain-stimulation reward. Behav Brain Res177:90-99.
29. Krook AL, Stokka D, Heger B, Nygaard E (2007). Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res13:216-221.
30. Larsson I, Landstrom LE, Lamer E, Lundgren E, Miorner H, Strannegard L (1978). Interferon production in glia and glioma cell lines. Infect Immun22: 786-789.
31. Li Y, Ye L, Peng JS, Wang CQ, Luo GX, Zhang T, et al. (2007). Morphine inhibits intrahepatic interferon- alpha expression and enhances complete hepatitis C virus replication. J Infect Dis196:719-730.
32. Loftis JM, Hauser P, Macey TA, Lowe JD (2006). Can rodents be used to model interferon-alpha-induced depressive symptoms? Prog Neuropsychopharmacol Biol Psychiatry 30:1364-1365; author reply 1366.
33. Lu L, Chen H, Su W, Ge X, Yue W, Su F, Ma L (2005). Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology (Berl)181:90-100.
34. Makino M, Kitano Y, Komlyama C, Hirohashi M, Kohno M, Moriyama M, et al. (2000a). Human interferon-alpha induces immobility In the mouse forced swimming test: involvement of the opioid system. Brain Res852:482- 484.
35. Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K (2000b). Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br J Pharmacol130: 1269-1274.
36. Matthews AM, Fireman M, Zucker B, Sobel M, Hauser P (2006). Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry163:1342-1347; quiz 1479.
37. Menzies RA, Patel R, Hall NR, O'Grady MP, Rier SE (1992). Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci50:PL227-PL232.
38. Mueller D, Stewart J (2000). Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Pes115:39-47.
39. Nakashima T, Murakami T, Mural Y, Hori T, Miyata S, Kiyohara T (1995). Naloxone suppresses the rising phase of fever induced by interferon-alpha. Brain Res Bull37:61-66.
40. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B (1999). Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet354:131-132.
41. Parker LA, McDonald RV (2000). Reinstatement of both a conditioned place preference and a conditioned place aversion with drug primes. Pharmacol Biochem Behav66:559-561.
42. Paxinos G, Watson C (1997). The rat brain in stereotaxic coordinates. 2nd ed. San Diego; Academic Press.
43. Pestka S, Langer JA, Zoon KC, Samuel CE (1987). Interferons and their actions. Annu Rev Biochem56:727-777.
44. Plata-Salaman CR (1991). Immunoregulators in the nervous system. Neurosci Biobehav Rev15:185-215.
45. Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, Tyor WR (1995). A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun9:366-377.
46. Samini M, Kardan A, Mehr SE (2008). Alpha-2 agonists decrease expression of morphine-induced conditioned place preference. Pharmacol Biochem Behav88:403-406.
47. Saphier D (1995). Neuroendocrine effects of interferon-alpha in the rat. Adv Exp Med Biol373:209-218.
48. Saphier D, Roerig SC, Ito C, Vlasak WR, Farrar GE, Broyles JE, Welch JE (1994). Inhibition of neural and neuroendocrine activity by alpha-lnterferon: neuroendocrine, electrophysiological, and biochemical studies In the rat. Brain Behav Immun8:37-56.
49. Shaham Y, Stewart J (1996). Effects of opioid and dopamine receptor antagonists on relapse induced by stress and re-exposure to heroin in rats. Psychopharmacology (Berl)125:385-391.
50. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl)168:3-20.
51. Stewart J (1984). Reinstatement of heroin and cocaine self-admlnistration behavior In the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacol Biochem Behav20:917-923.
52. Stewart J, Wise RA (1992). Reinstatement of heroin self-administration habits: morphine prompts and naltrexone discourages renewed responding after extinction. Psychopharmacology (Berl)108:79-84.
53. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, et al. (2005). Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther77:214-224.
54. Sylvestre DL (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend67:117-123.
55. Wang CQ, Li Y, Douglas SD, Wang X, Metzger DS, Zhang T, Ho WZ (2005). Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol167:1333-1340.
56. Wang J, Campbell IL, Zhang H (2008). Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry13:293-301.
57. Wang X, Cen X, Lu L (2001a). Noradrenaline in the bed nucleus of the stria terminalis is critical for stress-induced reactivation of morphine-conditioned place preference in rats. Eur J Pharmacol432: 153-161.
58. Wang YX, Cui GY, Shen J, Huang AJ, Liu XY, Chen YZ, Jiang CL (2001b). Analgesic domains of interferon-alpha. Neuroreport12:857-859.
59. Wang YX, Jiang CL, Lu CL, Song LX, You ZD, Shao XY, et al. (2000). Distinct domains of IFNalpha mediate Immune and analgesic effects respectively. J Neuroimmunol108:64-67.
60. Zhai HF, Zhang ZY, Zhao M, Qiu Y, Ghitza UE, Lu L (2007). Conditioned drug reward enhances subsequent spatial learning and memory in rats. Psychopharmacology (Berl)195:193-201.
61. Zhao M, Zhang ZY, Zhai HF, Qiu Y, Lu L (2007). Effects of stress during reactivation on rewarding memory. Neuroreport18:1153-1156.